FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214243748> ?p ?o ?g. }

• W3214243748 abstract "Targeted therapies have led to significant improvement in the management and prognosis of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). We performed a network meta-analysis of frontline treatment options of ALK-positive NSCLC to provide clinical guidance.PubMed, Embase, ClinicalTrials.gov, and international conference databases were searched to identify relevant trials from inception to June 30, 2021. Phase III randomized controlled trials (RCTs) comparing treatments for patients with ALK-positive advanced NSCLC in the first-line setting were included in a Bayesian network meta-analysis. Eligible studies reported at least one of the following clinical outcomes: progression-free survival (PFS), overall survival (OS), risk of the central nervous system (CNS) progression, adverse events (AEs) of grade (G) 3 or higher (G3 AEs), or serious AEs (SAEs). Hazard ratios (HRs) and CI for primary outcome of PFS and secondary outcome of OS and risk of CNS progression were obtained. A multivariate, consistency model, fixed-effects analysis was used in the network meta-analysis. Data on G3 AEs and SAEs were abstracted and meta-analyzed. Risk of bias (RoB) was assessed using the Cochrane Collaboration's tool.Nine RCTs comprising 2,484 patients were included with seven treatments: alectinib, brigatinib, ceritinib, crizotinib, ensartinib, lorlatinib, and chemotherapy. Compared with chemotherapy, ALK-tyrosine kinase inhibitors (TKIs) significantly prolong PFS and reduced risk of CNS progression except for ceritinib. Lorlatinib appears superior at reducing risk of CNS progression. None of the ALK-TKIs have a significantly prolonged OS as compared with chemotherapy. Lorlatinib increases the risk of G3 AEs as compared with alectinib (odds ratio 4.26 [95% CrI 1.22 to 15.53]), while alectinib caused the fewest G3 AEs.Lorlatinib is associated with the highest PFS benefit and lowest risk of CNS progression benefits for patients with advanced ALK-positive NSCLC, compared with other first-line treatments, but with higher toxicity. The implementation of a newer generation of ALK-TKIs in the first-line treatment of ALK-positive NSCLC into current clinical practice is evolving rapidly." @default.
• W3214243748 created "2021-11-22" @default.
• W3214243748 creator A5012052127 @default.
• W3214243748 creator A5028773984 @default.
• W3214243748 creator A5050456399 @default.
• W3214243748 creator A5053066562 @default.
• W3214243748 creator A5070121957 @default.
• W3214243748 creator A5073309453 @default.
• W3214243748 creator A5079409805 @default.
• W3214243748 creator A5090826648 @default.
• W3214243748 date "2021-11-08" @default.
• W3214243748 modified "2023-10-01" @default.
• W3214243748 title "Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis" @default.
• W3214243748 cites W2010619956 @default.
• W3214243748 cites W2028415754 @default.
• W3214243748 cites W2041835001 @default.
• W3214243748 cites W2091808438 @default.
• W3214243748 cites W2099530756 @default.
• W3214243748 cites W2136919572 @default.
• W3214243748 cites W2471664064 @default.
• W3214243748 cites W2581996620 @default.
• W3214243748 cites W2613260339 @default.
• W3214243748 cites W2624310346 @default.
• W3214243748 cites W2751382641 @default.
• W3214243748 cites W2794844459 @default.
• W3214243748 cites W2885875860 @default.
• W3214243748 cites W2887380463 @default.
• W3214243748 cites W2894476389 @default.
• W3214243748 cites W2939690516 @default.
• W3214243748 cites W3015280903 @default.
• W3214243748 cites W3022131485 @default.
• W3214243748 cites W3032353482 @default.
• W3214243748 cites W3084573408 @default.
• W3214243748 cites W3101089668 @default.
• W3214243748 cites W3137552976 @default.
• W3214243748 cites W3153125289 @default.
• W3214243748 cites W3171414071 @default.
• W3214243748 doi "https://doi.org/10.3389/fonc.2021.754768" @default.
• W3214243748 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8606689" @default.
• W3214243748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34820326" @default.
• W3214243748 hasPublicationYear "2021" @default.
• W3214243748 type Work @default.
• W3214243748 sameAs 3214243748 @default.
• W3214243748 citedByCount "11" @default.
• W3214243748 countsByYear W32142437482022 @default.
• W3214243748 countsByYear W32142437482023 @default.
• W3214243748 crossrefType "journal-article" @default.
• W3214243748 hasAuthorship W3214243748A5012052127 @default.
• W3214243748 hasAuthorship W3214243748A5028773984 @default.
• W3214243748 hasAuthorship W3214243748A5050456399 @default.
• W3214243748 hasAuthorship W3214243748A5053066562 @default.
• W3214243748 hasAuthorship W3214243748A5070121957 @default.
• W3214243748 hasAuthorship W3214243748A5073309453 @default.
• W3214243748 hasAuthorship W3214243748A5079409805 @default.
• W3214243748 hasAuthorship W3214243748A5090826648 @default.
• W3214243748 hasBestOaLocation W32142437481 @default.
• W3214243748 hasConcept C117643217 @default.
• W3214243748 hasConcept C126322002 @default.
• W3214243748 hasConcept C143998085 @default.
• W3214243748 hasConcept C168563851 @default.
• W3214243748 hasConcept C197934379 @default.
• W3214243748 hasConcept C207103383 @default.
• W3214243748 hasConcept C2776232967 @default.
• W3214243748 hasConcept C2776256026 @default.
• W3214243748 hasConcept C2776694085 @default.
• W3214243748 hasConcept C2779220645 @default.
• W3214243748 hasConcept C2779422266 @default.
• W3214243748 hasConcept C2779750558 @default.
• W3214243748 hasConcept C2780739268 @default.
• W3214243748 hasConcept C44249647 @default.
• W3214243748 hasConcept C71924100 @default.
• W3214243748 hasConcept C95190672 @default.
• W3214243748 hasConceptScore W3214243748C117643217 @default.
• W3214243748 hasConceptScore W3214243748C126322002 @default.
• W3214243748 hasConceptScore W3214243748C143998085 @default.
• W3214243748 hasConceptScore W3214243748C168563851 @default.
• W3214243748 hasConceptScore W3214243748C197934379 @default.
• W3214243748 hasConceptScore W3214243748C207103383 @default.
• W3214243748 hasConceptScore W3214243748C2776232967 @default.
• W3214243748 hasConceptScore W3214243748C2776256026 @default.
• W3214243748 hasConceptScore W3214243748C2776694085 @default.
• W3214243748 hasConceptScore W3214243748C2779220645 @default.
• W3214243748 hasConceptScore W3214243748C2779422266 @default.
• W3214243748 hasConceptScore W3214243748C2779750558 @default.
• W3214243748 hasConceptScore W3214243748C2780739268 @default.
• W3214243748 hasConceptScore W3214243748C44249647 @default.
• W3214243748 hasConceptScore W3214243748C71924100 @default.
• W3214243748 hasConceptScore W3214243748C95190672 @default.
• W3214243748 hasLocation W32142437481 @default.
• W3214243748 hasLocation W32142437482 @default.
• W3214243748 hasLocation W32142437483 @default.
• W3214243748 hasLocation W32142437484 @default.
• W3214243748 hasOpenAccess W3214243748 @default.
• W3214243748 hasPrimaryLocation W32142437481 @default.
• W3214243748 hasRelatedWork W1871221741 @default.
• W3214243748 hasRelatedWork W2516942920 @default.
• W3214243748 hasRelatedWork W2611981735 @default.
• W3214243748 hasRelatedWork W2624310346 @default.
• W3214243748 hasRelatedWork W2799723181 @default.
• W3214243748 hasRelatedWork W2887042787 @default.

• next